Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.

Journal of cancer research and clinical oncology - 1 Sept 2023

Cai Ruoxue, Zhu Hongyu, Liu Ying, Sha Huanhuan, Peng Weiwei, Yin Rong, Zhou Guoren, Fang Ying

Abstract excerpt

INTRODUCTION: Lung cancer is one of primary cancer type with high incidence and mortality, non-small cell lung cancer (NSCLC) is the most common type of lung cncer. For advanced lung cancer, traditional chemotherapy and targeted therapy become difficult to solve the dilemma of further progress. In recent years, with the clinical application of immunotherapy, the therapeutic strategy of lung cancer has changed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Helicases

Share to Immunotherapy

Share to Kelch-Like ECH-Associated Protein 1

Share to NF-E2-Related Factor 2

Share to Nuclear Proteins

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 37261523
DOI: 10.1007/s00432-023-04919-4
PMCID: PMC10423141

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.PMID 37261523Read ↗

[Research Progress of Immunotherapy for Non-small Cell Lung Cancer with Drive Gene Mutation].Semantic proximity Read ↗

A retrospective analysis of immunotherapy in non-small cell lung cancer patients with targetable genetic mutations.Semantic proximity Read ↗

Lung cancer and metastasis: new opportunities and challenges.Semantic proximity Read ↗

[Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations].Semantic proximity Read ↗

[Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Advances on driver oncogenes of non-small cell lung cancer].Semantic proximity Read ↗

Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacySemantic proximity Read ↗

[Emerging biomarker for immunotherapy of non-small cell lung cancer: tumor mutation burden (TMB) and latest progress in related research field].Semantic proximity Read ↗

Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.Semantic proximity Read ↗

[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition)].Semantic proximity Read ↗

NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance.Semantic proximity Read ↗

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.